Almost all new ‘cutting edge’ or practice changing cancer therapies are developed commercially, by private companies. This is deliberate, even strategic, on behalf of the public sector.
Not cost-effective does not mean not effective.
Is the Two-tier system failing patients?
https://twitter.com/mccarthymt7/status/1860385822953902315
“Private patients have swift access to European Medicines Agency (EMA) approved anti-cancer drugs, the charity said.
However public patients must wait on average two years to find out if they will get access to the same drugs.” Irish Cancer Society
https://www.rte.ie/news/health/2024/1122/1482285-cancer-health-funding/
Lynch Syndrome Ireland 